Emotional State Questionnaire (EST-Q)

Abstract

The Emotional State Questionnaire (EST-Q) is a standardized, self-report screening instrument developed to assess symptoms of common mental disorders, specifically major depression, generalized anxiety, panic disorder, agoraphobia, asthenia or chronic fatigue, and primary sleep disturbances. Originally developed in Estonia by Anu Aluoja and colleagues in 1999, the instrument was engineered to provide a rapid, psychometrically robust dimensional evaluation of affective and neurotic distress aligned with the diagnostic criteria of the International Classification of Diseases, Tenth Revision (ICD-10) and the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV).

The questionnaire consists of 33 original screening items (with 28 to 31 primary scored items forming its core empirical subscales), evaluated along a 5-point Likert-type response scale ranging from 0 (“not at all”) to 4 (“all the time”), capturing symptom frequency over the preceding four weeks. The core empirical subscales comprise Depression (8 items), Anxiety (6 items), Agoraphobia–Panic (5 items), Fatigue (5 items), and Insomnia (3 items). Across general population, primary care, and psychiatric inpatient samples, the EST-Q exhibits high internal consistency, with total scale Cronbach’s alpha coefficients typically reaching α = .88, and subscale alphas ranging from .69 for generalized anxiety to .87 for depression and .82 for agoraphobia-panic. Confirmatory and exploratory factor analyses substantiate a correlated five-factor structure that distinguishes general psychological distress from somatic exhaustion and situational phobic avoidance, demonstrating high sensitivity and specificity against structured diagnostic interviews such as the Mini-International Neuropsychiatric Interview (M.I.N.I.).

Keywords

Emotional State Questionnaire, EST-Q, depression assessment, generalized anxiety, panic disorder, agoraphobia, fatigue, insomnia, psychometrics, screening scale

Authors

The Emotional State Questionnaire was developed and validated by a multidisciplinary team of psychiatrists and clinical psychologists from the Department of Psychiatry at the University of Tartu and the National Institute for Health Development in Tallinn, Estonia:

• Anu Aluoja, PhD — Associate Professor of Clinical Psychology, Department of Psychiatry, Faculty of Medicine, University of Tartu, Estonia.
• Jakov Shlik, MD, PhD — Psychiatrist and Clinical Researcher, Department of Psychiatry, University of Tartu; affiliated with the Ottawa Hospital Research Institute / University of Ottawa, Canada.
• Veiko Vasar, MD, PhD — Late Professor and Chair of Psychiatry, Department of Psychiatry, Faculty of Medicine, University of Tartu, Estonia.
• Kadri Luuk, MSc — Department of Psychiatry, Faculty of Medicine, University of Tartu, Estonia.
• Mall Leinsalu, MD, PhD — Senior Research Fellow, Department of Epidemiology and Biostatistics, National Institute for Health Development, Tallinn, Estonia; Stockholm Centre for Health and Social Change, Södertörn University, Sweden.

Purpose

The primary purpose of the Emotional State Questionnaire (EST-Q) is to provide clinicians, clinical researchers, and epidemiologists with a reliable, valid, and time-efficient dimensional measure of affective and anxiety symptomatology. Psychiatric epidemiology and general primary healthcare have long faced the challenge of detecting comorbid and subsyndromal presentations of mood and anxiety conditions. Patients frequently present in outpatient clinics with diffuse, nonspecific somatic complaints, such as persistent fatigue, muscular tension, gastrointestinal disruptions, and sleep architecture disruptions, without spontaneous reporting of depressed mood or cognitive anxiety.

Consequently, the EST-Q was engineered to serve several distinct clinical and scientific functions:

• First-Line Clinical Screening: It offers high discriminant capability in primary care settings, alerting general practitioners to patients meeting clinical cutoffs for major depressive episodes, generalized anxiety disorder, panic disorder, or situational agoraphobia who might otherwise receive symptomatic treatment for somatoform complaints.
• Differential Syndromic Disentanglement: By parsing psychological distress into five dedicated subscales—Depression, Anxiety, Agoraphobia–Panic, Fatigue, and Insomnia—the EST-Q avoids treating neurotic distress as a monolithic construct, permitting targeted pharmacotherapeutic or psychotherapeutic intervention.
• Treatment Monitoring and Longitudinal Follow-Up: The 5-point metric assesses symptom frequency over a 4-week reporting window, providing adequate granularity to detect clinical response to selective serotonin reuptake inhibitors (SSRIs), cognitive-behavioral therapy (CBT), or sleep-hygiene protocols.
• Epidemiological Surveillance: The EST-Q was formulated to serve as a robust instrument in large-scale public health surveys evaluating the mental health status of adult populations, assessing socioeconomic, occupational, and physical health correlates of psychological morbidity.

Psychological Construct

The EST-Q conceptualizes neurotic and affective suffering through a multidimensional matrix reflecting five interrelated symptom clusters:

1. Depression

The Depression subscale captures the cardinal cognitive, affective, and motivational markers of unipolar depressive pathology as formulated in contemporary psychiatric taxonomies. It targets depressed mood (sadness), anhedonia (the pervasive incapacity to experience pleasure or interest), feelings of worthlessness, deliberate self-blame and self-accusation, pathological loneliness, pervasive hopelessness regarding the future, and suicidal ideation or recurrent thoughts of death. Rather than focusing primarily on secondary somatic manifestations, this dimension centers on the cognitive-affective core of depressive despair.

2. Generalized Anxiety

The Anxiety subscale measures state-trait manifestations of free-floating tension, apprehensive expectation, and autonomic hyperarousal. Items assess pervasive, excessive worry distributed across disparate life domains, inability to relax, acute somatic motor agitation (restlessness precluding sitting still), heightened startle response, subjective nervousness, and irritability. This construct delineates the persistent, anticipatory distress characteristic of Generalized Anxiety Disorder (GAD).

3. Agoraphobia–Panic

The Agoraphobia–Panic subscale evaluates acute, paroxysmal autonomic surges alongside situational avoidance behaviors. It measures catastrophic visceral sensations (e.g., sudden attacks of panic marked by palpitations, dyspnea, faintness, and terrifying somatic feelings) coupled with contextual fears: entering open spaces or crowded streets, remaining home alone, traveling by public transportation or motor vehicles, and public fainting. It models the classical phobic-avoidant conditioning that emerges secondary to panic attacks.

4. Asthenia / Fatigue

Distinguishable from primary cognitive depression, the Fatigue dimension operationalizes persistent, pathological depletion of physical and mental vitality. It indexes subjective exhaustion, rapid fatiguability, psychomotor slowing, and the cardinal sign of unrefreshing rest (sleep that fails to restore strength). This separation is vital in separating chronic fatigue syndrome, medical asthenia, and post-viral states from purely cognitive depressive disorders.

5. Insomnia

The Insomnia dimension monitors disruptions across the biological sleep cycle, specifically addressing initial insomnia (difficulty falling asleep), middle insomnia (fragmented, restless, or disturbed nocturnal maintenance), and terminal insomnia (early-morning awakening with inability to return to sleep). Isolating sleep disturbances allows researchers to assess whether sleep disturbance is an isolated symptom or an integral component of a broader mood episode.

Theoretical Framework

The theoretical architecture of the EST-Q rests upon the intersection of modern descriptive nosology (ICD-10 and DSM-IV) and quantitative structural models of common mental disorders, most notably the Tripartite Model of Anxiety and Depression formulated by Clark and Watson (1991).

Historically, psychological measurement struggled with high cross-scale correlations between self-reported anxiety and depression inventories, such as the Beck Depression Inventory (BDI) and the State-Trait Anxiety Inventory (STAI). Clark and Watson’s tripartite framework postulated that:

• A broad, nonspecific dimension labeled Negative Affectivity (general distress) is shared by both depressive and anxious syndromes.
• Physiological Hyperarousal (somatic tension, autonomic activation, sudden panic sensations) is unique to anxiety states, particularly panic and phobic pathology.
• Low Positive Affectivity (anhedonia, loss of interest, absence of joy, pervasive lethargy) is specific to depressive disorders.

Aluoja and colleagues designed the EST-Q to translate these dimensional boundaries into clinical assessment. By extracting distinct items for anhedonia and cognitive hopelessness (Depression), autonomic surges and situational avoidance (Agoraphobia–Panic), generalized apprehension (Anxiety), and physical energy depletion (Fatigue), the EST-Q permits empirical verification of whether a patient’s suffering represents undifferentiated general distress or distinct syndrome-specific pathologies requiring different therapeutic approaches.

Validity

Validation studies of the EST-Q across primary care cohorts, psychiatric clinical samples, and representative general population registries have established sound psychometric properties:

Construct and Factorial Validity

Exploratory factor analyses (EFA) employing principal axis factoring with promax and varimax rotations, alongside Confirmatory Factor Analyses (CFA), have corroborated the theoretical multi-subscale structure. Rather than collapsing into a single general distress factor, goodness-of-fit indices support the correlated 5-factor model (Comparative Fit Index [CFI] > .92; Root Mean Square Error of Approximation [RMSEA] < .06), demonstrating clear empirical demarcation among depression, panic-agoraphobia, generalized anxiety, fatigue, and insomnia.

Convergent and Discriminant Validity

The EST-Q subscales demonstrate robust convergent validity when benchmarked against established international psychometric scales:

• The EST-Q Depression subscale correlates strongly with the Beck Depression Inventory (r = .78 to .84) and the Montgomery–Åsberg Depression Rating Scale (MADRS; r = .72).
• The EST-Q Anxiety subscale exhibits high correlations with the Spielberger State-Trait Anxiety Inventory (STAI-Trait, r = .71 to .76) and the Hamilton Anxiety Rating Scale (HAM-A).
• The EST-Q Agoraphobia–Panic subscale successfully separates patients presenting with acute panic disorder and agoraphobic avoidance from patients presenting with generalized social anxiety or isolated obsessive-compulsive symptoms.
• Discriminant validity is evidenced by the subscales’ ability to distinguish clinical psychiatric outpatients from healthy controls, with large effect sizes (Cohen’s d > 1.2 across all subscales).

Criterion and Diagnostic Predictive Validity

Using Receiver Operating Characteristic (ROC) analyses against structured psychiatric interviews (e.g., M.I.N.I. and SCAN), the EST-Q subscales demonstrate high diagnostic accuracy. In the original validation study by Aluoja et al. (1999):

• Depression subscale: An established cutoff score of ≥ 12 yields a sensitivity of approximately 88% and a specificity of 82% for detecting ICD-10/DSM-IV Depressive Episodes.
• Anxiety subscale: A cutoff score of ≥ 11 or ≥ 12 provides a sensitivity of 76% and a specificity of 78% for Generalized Anxiety Disorder.
• Agoraphobia–Panic subscale: A cutoff score of ≥ 7 discriminates panic disorder and situational agoraphobia with sensitivity exceeding 80% and specificity approaching 85%.

Reliability

The EST-Q displays consistent reliability profiles across research investigations and healthcare environments:

Internal Consistency

In the foundational psychometric study conducted by Aluoja et al. (1999) involving both general population cohorts (N = 551) and psychiatric patients (N = 122), internal consistency estimates (Cronbach’s α) were established as follows:

• Total EST-Q Scale: α = .88
• Depression Subscale (8 items): α = .87
• Agoraphobia–Panic Subscale (5 items): α = .82
• Fatigue Subscale (5 items): α = .77
• Insomnia Subscale (3 items): α = .76
• Anxiety Subscale (6 items): α = .69 (with subsequent validation studies observing values up to α = .75 in clinical populations)

Test-Retest Stability

Evaluation of test-retest reliability across non-clinical cohorts over a 2- to 4-week test-retest interval demonstrates high intraclass correlation coefficients (ICC = .80 to .86 for Depression; ICC = .74 to .81 for Anxiety and Panic). In clinical intervention trials, the scale exhibits high sensitivity to clinical change, reflecting significant score decrements among pharmacologically treated patients showing clinical remission.

Factor Analysis

The original development of the EST-Q utilized exploratory factor analysis (EFA) on a pool of candidate items extracted from ICD-10 diagnostic guidelines. Principal component analysis followed by oblique rotation revealed a clear five-factor solution accounting for over 52% of the total variance:

• Factor 1 (Depression): Dominated by high loadings from items reflecting sadness (Item 1, loading > .70), loss of interest/anhedonia (Item 3, loading > .68), feelings of worthlessness (Item 5), self-accusations (Item 6), suicidal thoughts (Item 7), loneliness (Item 16), and hopelessness (Item 17).
• Factor 2 (Agoraphobia–Panic): Defined by high loadings for panic attacks with autonomic arousal (Item 25, loading > .65), fear of being outside alone (Item 27/29), fear of open streets (Item 28/30), fear of fainting in public (Item 29/31), and fear of transport (Item 30/32).
• Factor 3 (Anxiety): Characterized by high loadings for generalized autonomic and motor tension: feeling anxious/fearful (Item 20), difficulty relaxing (Item 22), excessive worry (Item 23), motor restlessness (Item 24), irritability (Item 2), and startle reactivity (Item 26).
• Factor 4 (Fatigue): Marked by loadings on fatigue/loss of energy (Item 4), feeling slowed down (Item 9), unrefreshing rest (Item 19), and easy fatigability (Item 21).
• Factor 5 (Insomnia): Defined by items measuring initial insomnia (Item 10), broken nocturnal sleep (Item 11), and early-morning terminal awakening (Item 12).

Subsequent Confirmatory Factor Analyses (CFA) conducted on later revisions (such as the EST-Q-2) have substantiated the distinctiveness of these factors, confirming that a hierarchical structure (five first-order factors loading onto a higher-order general distress construct) or a correlated five-factor model achieves superior fit compared to single-factor unidimensional models.

Instrument / Measurement Tool

• Instrument Name: Emotional State Questionnaire (EST-Q)
• Test Type: Self-report screening inventory and clinical symptom rating scale
• Item Count: 33 total items (28 to 31 primary scored items comprising the diagnostic subscales)
• Response Format: 5-point Likert scale (0 to 4):
  • 0 = Not at all
  • 1 = Seldom
  • 2 = Sometimes
  • 3 = Often
  • 4 = All the time
• Recall Period: Symptoms experienced during the preceding four weeks (past month)
• Subscales & Scoring Formulas:
  • Depression (8 items): Sum of items 1, 3, 5, 6, 7, 16, 17, and 18 (Score range: 0–32; clinical cutoff ≥ 12)
  • Anxiety (6 items): Sum of items 2, 20, 22, 23, 24, and 26 (Score range: 0–24; clinical cutoff ≥ 11 or 12)
  • Agoraphobia–Panic (5 items): Sum of items 25, 27, 28, 29, and 30 [designated 25, 29, 30, 31, 32 in extended numbering] (Score range: 0–20; clinical cutoff ≥ 6 or 7)
  • Fatigue (5 items): Sum of items 4, 5, 9, 19, and 21 (Score range: 0–20; clinical cutoff ≥ 7)
  • Insomnia (3 items): Sum of items 10, 11, and 12 (Score range: 0–12; clinical cutoff ≥ 6 or 7)
• Administration Time: Approximately 5 to 10 minutes
• Target Population: Adults and adolescents aged 16 years and older in clinical and non-clinical settings

Permissions & Fee and Test Year

The Emotional State Questionnaire (EST-Q) was published in 1999 by Anu Aluoja, Jakov Shlik, Veiko Vasar, Kadri Luuk, and Mall Leinsalu in the Nordic Journal of Psychiatry. The questionnaire was developed as a non-commercial, public-domain academic instrument to facilitate mental health screening, psychiatric epidemiology, and clinical care. It may be utilized freely for non-commercial academic research, healthcare screening, and clinical monitoring without licensing fees, provided proper attribution is given to the original authors and publication.

References

• Aluoja, A., Shlik, J., Vasar, V., Luuk, K., & Leinsalu, M. (1999). Development and psychometric properties of the Emotional State Questionnaire, a self-report questionnaire for depression and anxiety. Nordic Journal of Psychiatry, 53(6), 443–449. https://doi.org/10.1080/080394899427692
• Aluoja, A., Leinsalu, M., Shlik, J., Vasar, V., & Luuk, K. (2004). Symptoms of depression and anxiety in Estonia: Prevalence and socio-demographic correlation. European Psychiatry, 19(5), 291–297. https://doi.org/10.1016/j.eurpsy.2004.04.011
• Clark, L. A., & Watson, D. (1991). Tripartite model of anxiety and depression: Psychometric evidence and taxonomic implications. Journal of Abnormal Psychology, 100(3), 316–336. https://doi.org/10.1037/0021-843X.100.3.316
• Kõlves, K., Aluoja, A., & Leinsalu, M. (2006). Psychometric properties of the Estonian version of the Emotional State Questionnaire (EST-Q-2). Estonian Medical Journal (Eesti Arst), 85(11), 748–754.
• World Health Organization. (1992). The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. World Health Organization. https://apps.who.int/iris/handle/10665/37958

Items of the Scale